Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

753 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Optimal management of radiation pneumonitis: Findings of an international Delphi consensus study.
Voruganti Maddali IS, Cunningham C, McLeod L, Bahig H, Chaudhuri N, L M Chua K, Evison M, Faivre-Finn C, Franks K, Harden S, Videtic G, Lee P, Senan S, Siva S, Palma DA, Phillips I, Kruser J, Kruser T, Peedell C, Melody Qu X, Robinson C, Wright A, Harrow S, Louie AV. Voruganti Maddali IS, et al. Among authors: phillips i. Lung Cancer. 2024 Jun;192:107822. doi: 10.1016/j.lungcan.2024.107822. Epub 2024 May 14. Lung Cancer. 2024. PMID: 38788551
In Response to: 'Should We be Offering our Patients with Oligometastases Stereotactic Ablative Body Radiotherapy?' by Ostler et al. and 'Should We be Offering our Patients with Oligometastases Stereotactic Ablative Body Radiotherapy - No' by Macbeth and Hughes-Davies.
Phillips I, Olson R, Palma D, Harrow S. Phillips I, et al. Clin Oncol (R Coll Radiol). 2022 Apr;34(4):e169-e170. doi: 10.1016/j.clon.2022.01.041. Epub 2022 Feb 8. Clin Oncol (R Coll Radiol). 2022. PMID: 35148914 No abstract available.
Single vs. multiple fraction non-inferiority trial of stereotactic ablative radiotherapy for the comprehensive treatment of oligo-metastases/progression: SIMPLIFY-SABR-COMET.
Olson R, Abraham H, Leclerc C, Benny A, Baker S, Matthews Q, Chng N, Bergman A, Mou B, Dunne EM, Schellenberg D, Jiang W, Chan E, Atrchian S, Lefresne S, Carolan H, Valev B, Tyldesley S, Bang A, Berrang T, Clark H, Hsu F, Louie AV, Warner A, Palma DA, Howell D, Barry A, Dawson L, Grendarova P, Walker D, Sinha R, Tsai J, Bahig H, Thibault I, Koul R, Senthi S, Phillips I, Grose D, Kelly P, Armstrong J, McDermott R, Johnstone C, Vasan S, Aherne N, Harrow S, Liu M. Olson R, et al. Among authors: phillips i. BMC Cancer. 2024 Feb 3;24(1):171. doi: 10.1186/s12885-024-11905-7. BMC Cancer. 2024. PMID: 38310262 Free PMC article.
Real-World Impact of SABR on Stage I Non-Small-Cell Lung Cancer Outcomes at a Scottish Cancer Centre.
Stares M, Lewis G, Vallet M, Killean A, Tramonti G, Patrizio A, Mackean M, Harrow S, Barrie C, MacLennan K, Campbell S, Evans T, Tufail A, Edinburgh Cancer Informatics Programme, Hall P, Phillips I. Stares M, et al. Among authors: phillips i. Cancers (Basel). 2023 Feb 23;15(5):1431. doi: 10.3390/cancers15051431. Cancers (Basel). 2023. PMID: 36900224 Free PMC article.
Biomarkers of systemic inflammation predict survival with first-line immune checkpoint inhibitors in non-small-cell lung cancer.
Stares M, Ding TE, Stratton C, Thomson F, Baxter M, Cagney H, Cumming K, Swan A, Ross F, Barrie C, Maclennan K, Campbell S, Evans T, Tufail A, Harrow S, Lord H, Laird B, MacKean M, Phillips I. Stares M, et al. Among authors: phillips i. ESMO Open. 2022 Apr;7(2):100445. doi: 10.1016/j.esmoop.2022.100445. Epub 2022 Apr 7. ESMO Open. 2022. PMID: 35398717 Free PMC article.
753 results